Literature DB >> 11222205

Targeted transarterial oily chemoembolization for small foci of hepatocellular carcinoma using a unified helical CT and angiography system: analysis of factors affecting local recurrence and survival rates.

K Takayasu1, Y Muramatsu, T Maeda, R Iwata, H Furukawa, Y Muramatsu, N Moriyama, T Okusaka, S Okada, H Ueno.   

Abstract

OBJECTIVE: We assessed the local recurrence rate after a single targeted transarterial oily chemoembolization for small hepatocellular carcinoma with the unified helical CT and angiography system and analyzed the factors affecting the local recurrence rate and survival rate with Cox proportional hazards model.
MATERIALS AND METHODS: For 54 consecutive patients with 71 small hepatocellular carcinomas (< or = 5 cm) with no more than two associated lesions, targeted oily chemoembolization was performed with an emulsion of doxorubicin hydrochloride mixed with iodized oil or a suspension of zinostatin stimalamer followed by gelatin sponge particles. When local recurrence or a new lesion appeared, follow-up targeted oily chemoembolization was performed.
RESULTS: For 52 of 71 lesions, the catheterization to a subsegmental or more distal feeding artery could be performed. Local recurrence was recognized in 33.2% at 1 year and 37.8% at 2 and 3 years. The significant factors that affected local recurrence were tumor size (p = 0.005) and degree of deposition of iodized oil within the lesion (p = 0.049). The survival rates at 1, 2, and 3 years were 93.3%, 77.1%, and 77.1%, respectively. The significant factors affecting survival rate were tumor thrombus in large vessels (p = 0.0001), appearing after the first chemoembolization, and maximum tumor size (p = 0.022).
CONCLUSION: Single targeted transarterial oily chemoembolization with the unified helical CT and angiography system had a low local recurrence rate for small hepatocellular carcinoma, and follow-up embolization resulted in a good survival rate. Tumor size along with degree of intratumoral iodized oil deposition and tumor thrombus along with maximum tumor size were significant factors affecting local recurrence and survival rate, respectively.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11222205     DOI: 10.2214/ajr.176.3.1760681

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  47 in total

1.  Computed tomography-guided transarterial chemoembolization as the initial therapy for hepatocellular carcinoma: experience of 75 cases in a single institute.

Authors:  Yoichi Okada; Hiroyasu Ina; Kazunori Kubota; Yoshiro Himeno; Toshihiko Wakita; Isamu Ohashi; Naoya Gomi; Tetsuo Yoshida; Sunao Mae; Tetsuya Irie
Journal:  Dig Dis Sci       Date:  2003-03       Impact factor: 3.199

2.  A novel transcatheter arterial infusion chemotherapy using iodized oil and degradable starch microspheres for hepatocellular carcinoma: a prospective randomized trial.

Authors:  Takahiro Yamasaki; Satoe Hamabe; Issei Saeki; Yohei Harima; Yuhki Yamaguchi; Koichi Uchida; Shuji Terai; Isao Sakaida
Journal:  J Gastroenterol       Date:  2010-08-25       Impact factor: 7.527

3.  Hepatic arterial embolization for unresectable hepatocellular carcinomas: do technical factors affect prognosis?

Authors:  Koichiro Yamakado; Shiro Miyayama; Shozo Hirota; Kimiyoshi Mizunuma; Kenji Nakamura; Yoshitaka Inaba; Akihiro Maeda; Kunihiro Matsuo; Norifumi Nishida; Takeshi Aramaki; Hiroshi Anai; Shinichi Koura; Shigeo Oikawa; Ken Watanabe; Taku Yasumoto; Kinya Furuichi; Masato Yamaguchi
Journal:  Jpn J Radiol       Date:  2012-05-30       Impact factor: 2.374

4.  Quality of life after radiofrequency ablation combined with transcatheter arterial chemoembolization for hepatocellular carcinoma: comparison with transcatheter arterial chemoembolization alone.

Authors:  Yan-Bin Wang; Min-Hua Chen; Kun Yan; Wei Yang; Ying Dai; Shan-Shan Yin
Journal:  Qual Life Res       Date:  2006-11-17       Impact factor: 4.147

5.  Intraprocedural 3D Quantification of Lipiodol Deposition on Cone-Beam CT Predicts Tumor Response After Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma.

Authors:  Zhijun Wang; Rongxin Chen; Rafael Duran; Yan Zhao; Gayane Yenokyan; Julius Chapiro; Rüdiger Schernthaner; Alessandro Radaelli; MingDe Lin; Jean-François Geschwind
Journal:  Cardiovasc Intervent Radiol       Date:  2015-05-23       Impact factor: 2.740

Review 6.  Efficacy of cone-beam computed tomography during transcatheter arterial chemoembolization for hepatocellular carcinoma.

Authors:  Shiro Miyayama; Masashi Yamashiro; Yuki Hattori; Nobuaki Orito; Ken Matsui; Kazunobu Tsuji; Miki Yoshida; Osamu Matsui
Journal:  Jpn J Radiol       Date:  2011-07-24       Impact factor: 2.374

7.  Quantitative assessment of lipiodol deposition after chemoembolization: comparison between cone-beam CT and multidetector CT.

Authors:  Rongxin Chen; Jean-François Geschwind; Zhijun Wang; Vania Tacher; MingDe Lin
Journal:  J Vasc Interv Radiol       Date:  2013-10-01       Impact factor: 3.464

8.  Treatment strategy for hepatocellular carcinoma: expanding the indications for radiofrequency ablation.

Authors:  Ryosuke Tateishi; Shuichiro Shiina; Takamasa Ohki; Takahisa Sato; Ryota Masuzaki; Jun Imamura; Eriko Goto; Tadashi Goto; Hideo Yoshida; Shuntaro Obi; Shinpei Sato; Fumihiko Kanai; Haruhiko Yoshida; Masao Omata
Journal:  J Gastroenterol       Date:  2009-01-16       Impact factor: 7.527

9.  Tracking Navigation Imaging of Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma Using Three-Dimensional Cone-Beam CT Angiography.

Authors:  Yasunori Minami; Yukinobu Yagyu; Takamichi Murakami; Masatoshi Kudo
Journal:  Liver Cancer       Date:  2014-03       Impact factor: 11.740

10.  Risk factors for local tumor recurrence after segmental transarterial chemoembolization for hepatocellular carcinoma: the importance of tumor located in the segmental border zone.

Authors:  Yun Ku Cho; Jin Wook Chung; Yong-Sik Ahn; Yoon-Ok Park; Jae Kyun Kim; Jong-Hoon Byun
Journal:  Korean J Radiol       Date:  2006 Oct-Dec       Impact factor: 3.500

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.